Difference between revisions of "QMS"
(Get a job http://www.waynehastings.net/sucramal order sucramal Separately, the administration also announced a schedule in next year's open enrollment season. It will start on Nov. 15, 2014, a month) |
(Where do you come from? http://www.waynehastings.net/order-sumetrolim cheap sumetrolim LYNBROOK, N.Y., Dec. 6, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical) |
||
| Line 1: | Line 1: | ||
| − | + | Where do you come from? http://www.waynehastings.net/order-sumetrolim cheap sumetrolim LYNBROOK, N.Y., Dec. 6, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S and XIAPEX(R) in the EU, today announced that the U.S. Food & Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) submitted by BioSpecifics' partner Auxilium Pharmaceuticals, Inc. (Auxilium) for XIAFLEX, an in-office, biologic for this treatment of Peyronie's disease. This is the first and only FDA-approved biologic therapy indicated for the treatment of Peyronie's disease in men with a palpable plaque and a curvature of 30 degrees or greater at the start of therapy. XIAFLEX is already approved in the U.S., EU, Canada and Australia for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm. | |
Revision as of 11:53, 29 January 2015
Where do you come from? http://www.waynehastings.net/order-sumetrolim cheap sumetrolim LYNBROOK, N.Y., Dec. 6, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S and XIAPEX(R) in the EU, today announced that the U.S. Food & Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) submitted by BioSpecifics' partner Auxilium Pharmaceuticals, Inc. (Auxilium) for XIAFLEX, an in-office, biologic for this treatment of Peyronie's disease. This is the first and only FDA-approved biologic therapy indicated for the treatment of Peyronie's disease in men with a palpable plaque and a curvature of 30 degrees or greater at the start of therapy. XIAFLEX is already approved in the U.S., EU, Canada and Australia for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm.
